Humphrey Taylor

This time, powerful interest groups (like pharma) that sank the Clinton healthcare bill are on the side of change

Americans take top spots in disease prevalence

As I work with pharma companies, I'm often asked "When will we get major reform of the healthcare system?" and "What will the reformed system look like?" And sometimes "How will we get there?" This is not the same as asking "How should we reform the system?" Or "What should a reformed system look like?"

If pharma is seen as a genuine contributor to the policy debate on comparative effectiveness, it could influence funding, pricing, and coverage decisions